|Articles|April 16, 2014

Clinical Trial Watch April 2014

This list of U.S.-based National Institutes of Health trials is derived from the NIH’s database and includes phase I-IV hypogonadism and BPH trials that are currently recruiting participants.

This list of U.S.-based National Institutes of Health trials is derived from the NIH’s database and includes phase I-IV hypogonadism and BPH trials that are currently recruiting participants. This list is current as of April 7, 2014. For more information, view the complete database at http://ClinicalTrials.gov.

Hypogonadism

LutrePulse Hypogonadotropic Hypogonadism

Sponsor(s): Ferring Pharmaceuticals

Identifier: NCT01976728

 

Oral Testosterone for the Treatment of Hypogonadism

Sponsor(s): TesoRx Pharma, LLC

Identifier: NCT01717768

 

Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism

Sponsor/Collaborators: Lipocine Inc.; INC Research; PPD

Identifier: NCT02081300

 

Testosterone Replacement for Male Opioid Agonist Maintained Patients

Sponsor(s): Yale University

Identifier: NCT01873989

 

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Sponsor(s): Repros Therapeutics Inc.

Identifier: NCT01993212

Continue to next page for more trials.

 

 

Testosterone Replacement in Men With Diabetes and Obesity

Sponsor/Collaborators: Kaleida Health; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Identifier: NCT01127659

 

Clomid in Men With Low Testosterone With and Without Prior Treatment

Sponsor(s): Phoenix VA Health Care System

Identifier: NCT01904734

 

Administration of Kisspeptin to Subjects With Reproductive Disorders

Sponsor(s): Massachusetts General Hospital

Identifier: NCT00914823

 

Testosterone and Pain Sensitivity

Sponsor/Collaborators: Johns Hopkins University; Endo Pharmaceuticals

Identifier: NCT01689896

 

Pulsatile GnRH in Anovulatory Infertility

Sponsor/Collaborators: Massachusetts General Hospital; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Identifier: NCT00383656

 

 

Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration

Sponsor(s): Weill Medical College of Cornell University

Identifier: NCT01880086

 

A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

Sponsor(s): Eli Lilly and Company

Identifier: NCT01816295

 

CYP19A1 Gene and Pharmacogenetics of Response to Testosterone Therapy

Sponsor(s): Department of Veterans Affairs

Identifier: NCT01378299

 

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

Sponsor(s): Massachusetts General Hospital

Identifier: NCT01438073

 

 

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

Sponsor(s): AbbVie

Identifier: NCT02082197

 

Testosterone and Alendronate in Hypogonadal Men

Sponsor/Collaborators: Massachusetts General Hospital; Endo Pharmaceuticals; Merck Sharp & Dohme Corp.

Identifier: NCT01460654

 

Kisspeptin in the Evaluation of Delayed Puberty

Sponsor(s): Massachusetts General Hospital

Identifier: NCT01438034

 

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

Sponsor(s): Repros Therapeutics Inc.

Identifier: NCT01923857

Continue to next page for BPH trials.

 

BPH

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

Sponsor(s): Nymox Corporation

Identifier: NCT01846793

 

Post-Marketing Study Using PROLIEVE for the Treatment of Benign Prostatic Hyperplasia (BPH)

Sponsor(s): Medifocus, Inc.

Identifier: NCT02021032

 

Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia

Sponsor(s): Merit Medical Systems, Inc.

Identifier: NCT01789840

 

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

Sponsor(s): Sophiris Bio Corp

Identifier: NCT01966614

 

Prostate Embolization for Benign Prostatic Hyperplasia

Sponsor/Collaborators: Georgetown University; James B. Spies, MD

Identifier: NCT01924988

 

Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms (BPH)

Sponsor(s): Department of Veterans Affairs

Identifier: NCT01589263

 

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

Sponsor(s): Ausio Pharmaceuticals, LLC

Identifier: NCT00962390

Subscribe to Urology Times to get monthly news from the leading news source for urologists.
 


Related to this article

Rethinking Testosterone Therapy After the FDA Label Revisions
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.